Free Trial

Kezar Life Sciences (KZR) Competitors

Kezar Life Sciences logo
$6.19 -0.15 (-2.37%)
As of 01/17/2025 04:00 PM Eastern

KZR vs. NLTX, ZNTL, PRQR, CRDF, CGEN, ACRS, SLN, CYBN, SCPH, and GNFT

Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Neoleukin Therapeutics (NLTX), Zentalis Pharmaceuticals (ZNTL), ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Compugen (CGEN), Aclaris Therapeutics (ACRS), Silence Therapeutics (SLN), Cybin (CYBN), scPharmaceuticals (SCPH), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry.

Kezar Life Sciences vs.

Neoleukin Therapeutics (NASDAQ:NLTX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.

Neoleukin Therapeutics' return on equity of -37.22% beat Kezar Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Neoleukin TherapeuticsN/A -37.22% -30.91%
Kezar Life Sciences N/A -54.95%-46.11%

In the previous week, Neoleukin Therapeutics and Neoleukin Therapeutics both had 1 articles in the media. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Kezar Life Sciences' score of -0.01 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neoleukin Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kezar Life Sciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kezar Life Sciences received 86 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 56.90% of users gave Kezar Life Sciences an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.

CompanyUnderperformOutperform
Neoleukin TherapeuticsOutperform Votes
50
45.87%
Underperform Votes
59
54.13%
Kezar Life SciencesOutperform Votes
136
56.90%
Underperform Votes
103
43.10%

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

Kezar Life Sciences has a consensus price target of $39.50, indicating a potential upside of 538.13%. Given Kezar Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Kezar Life Sciences is more favorable than Neoleukin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Kezar Life Sciences
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neoleukin Therapeutics has higher earnings, but lower revenue than Kezar Life Sciences. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.34
Kezar Life Sciences$7M6.46-$101.87M-$13.18-0.47

Summary

Kezar Life Sciences beats Neoleukin Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Kezar Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KZR vs. The Competition

MetricKezar Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$45.19M$6.21B$5.20B$9.14B
Dividend YieldN/A2.94%5.13%4.02%
P/E Ratio-0.479.2687.2517.09
Price / Sales6.46309.921,263.9177.22
Price / CashN/A61.4443.7736.04
Price / Book0.246.055.314.79
Net Income-$101.87M$154.90M$122.54M$224.99M
7 Day Performance-0.32%1.35%1.44%2.37%
1 Month Performance-2.98%0.41%2.51%4.40%
1 Year Performance-25.42%3.08%25.32%20.10%

Kezar Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KZR
Kezar Life Sciences
3.9188 of 5 stars
$6.19
-2.4%
$39.50
+538.1%
-25.4%$45.19M$7M-0.4760High Trading Volume
NLTX
Neoleukin Therapeutics
N/A$19.58
-8.9%
N/A-44.8%$184.01MN/A-6.3090High Trading Volume
ZNTL
Zentalis Pharmaceuticals
2.9394 of 5 stars
$2.56
-6.9%
$10.00
+290.6%
-82.6%$182.44M$40.56M-1.03160Positive News
PRQR
ProQR Therapeutics
2.7742 of 5 stars
$2.19
-9.5%
$8.83
+303.3%
+13.9%$178.88M$17.88M-6.84180
CRDF
Cardiff Oncology
2.1478 of 5 stars
$3.44
-4.7%
$10.33
+200.4%
+128.5%$175.90M$688,000.00-3.6620Positive News
CGEN
Compugen
2.2713 of 5 stars
$1.97
+20.1%
$4.00
+103.0%
+16.0%$175.80M$59.85M98.5070High Trading Volume
ACRS
Aclaris Therapeutics
4.0912 of 5 stars
$2.46
-0.4%
$11.00
+347.2%
+125.4%$175.72M$27.08M-4.7386Short Interest ↑
SLN
Silence Therapeutics
2.1074 of 5 stars
$5.86
-2.2%
$57.20
+876.1%
-72.2%$175.38M$16.25M-3.73100
CYBN
Cybin
2.9361 of 5 stars
$8.70
-2.1%
$138.00
+1,486.2%
N/A$173.93MN/A-1.3150Positive News
SCPH
scPharmaceuticals
3.3354 of 5 stars
$3.46
+1.8%
$15.00
+333.5%
-38.6%$173.14M$30.28M-1.8230
GNFT
Genfit
1.6456 of 5 stars
$3.44
-4.4%
$13.00
+277.9%
+4.9%$171.99M$76.06M0.00120Short Interest ↑

Related Companies and Tools


This page (NASDAQ:KZR) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners